Posts

Posted on

AMGEN’S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

PR Newswire

MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes 

New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes

Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT 


THOUSAND OAKS, Calif.
, June 18, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase 3 FOURIER study of Repatha® (evolocumab) in cardiovascular disease and the VESALIUS-REAL study of real-world lipid management patterns at the 85th American Diabetes Association (ADA) Scientific Sessions taking place from June 20–23, 2025, in Chicago.

Data for MariTide, an investigational long-acting peptide-antibody conjugate subcutaneously administered monthly or less frequently, will be presented during an expert-led Symposium being held on Monday, June 23 from 1:30 p.m. – 3:00 p.m. CDT. The Symposium will highlight 52-week efficacy, safety and tolerability data from Part 1 of the Phase 2 study, complete data from the primary analysis of the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study, and additional information on the Phase 3 MARITIME Chronic Weight Management studies. Topline results from Part 1 of the Phase 2 study were announced in November 2024.  

“We look forward to sharing results from our cardiometabolic research at the upcoming ADA meeting, which include 52-week data from Part 1 of the Phase 2 MariTide study showing robust weight loss without a weight loss plateau in people living with obesity, with and without Type 2 diabetes,” said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. “These findings have been pivotal in shaping the design of our Phase 3 MARITIME program, and we’re confident these studies will continue to demonstrate the potential of MariTide as a unique and differentiated option for people living with obesity and related conditions.”

Amgen will host a webcast call for the investment community in conjunction with the ADA Scientific Sessions on Monday, June 23 at 4:30 p.m. CDT. Jay Bradner, M.D., executive vice president of Research and Development at Amgen, along with other members of Amgen’s management team, will discuss the MariTide program. The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

At the Scientific Sessions, Amgen will also sponsor the ADA Interactive Obesity Experience. Throughout the meeting, attendees will have the opportunity to contribute to a word cloud project in the Exhibit Hall (Booth #1338) and participate in an immersive video experience in the ADA Member Lounge.

The 85th Scientific Sessions will not be livestreamed. On-Demand will open on Wednesday, June 25, 2025, following the meeting. Key Amgen posters and presentations include:

Obesity

  • Symposium:
    Once-Monthly MariTide for the Treatment of Obesity in People with or without Type 2 Diabetes: A 52-Week Phase 2 Study
    Session: Monday, June 23 from 1:30 p.m. – 3:00 p.m. CDT, Location: W375 A

Cardiovascular and Repatha

  • Cardiovascular Efficacy of Evolocumab in
    Persons with Type 1 Diabetes Mellitus: Insights
    from FOURIER Trial
    Abstract #1991, Abstract Session: Sunday, June 22 from 12:30 p.m. – 1:30 p.m. CDT
  • Lipid-lowering Therapy Patterns of High-risk Cardiovascular Patients without Prior Myocardial Infarction or Stroke: Vesalius-Real – Results from Patients with High-risk Diabetes in the U.S.
    Abstract #1315, Abstract Session: Saturday, June 21 from 12:30 p.m. – 1:30 p.m. CDT

About Obesity

Obesity is a complex biological disease that increases the risk of many other serious diseases and conditions, including Type 2 diabetes, heart failure, kidney disease, sleep apnea, atherosclerotic cardiovascular disease and metabolic dysfunction-associated steatohepatitis. The worldwide prevalence of obesity more than doubled between 1990 and 2022. In the U.S., more than two in five adults (42.5%) are living with obesity. In 2022, 890 million adults (18 years and older) globally were living with obesity, and 2.5 billion adults were living with overweight.

Obesity is linked to a marked reduction in quality of life and an array of serious medical complications and conditions. Despite the breadth of the disease, the formal recognition of obesity as a chronic disease by the American Medical Association (2013) and the European Health Commission (2021), and medical guidelines recommending pharmacologic treatment in appropriate individuals, only 1%-3% of eligible adults in the U.S. are prescribed medication for chronic weight management.

About MariTide 
MariTide is a bispecific glucagon-like peptide 1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist being investigated for the treatment of obesity and Type 2 diabetes mellitus. As a pioneering peptide-antibody conjugate molecule with a long half-life and dual mechanism of action, MariTide may allow for greater durability or reduce the likelihood of weight regain after treatment stops. Amgen used its genetic expertise to identify GIP receptor inhibition as a key factor in reducing body mass, an insight that led to MariTide’s development. Pre-clinical studies have demonstrated that simultaneously activating GLP-1 and inhibiting GIP pathways had a stronger effect on weight loss than targeting either GLP-1 or GIP receptors alone.

A primary clinical goal for people living with obesity or overweight is to achieve weight loss, and avoid weight regain thereby improving health. Given the heterogeneity of obesity and the number of people impacted, a variety of approaches will be needed. In addition to MariTide, Amgen is also advancing an obesity pipeline, which includes both oral and injectable approaches, composed of both incretin and non-incretin mechanisms.

Amgen’s Cardiovascular Ambition

Cardiovascular disease is a leading public health crisis in the United States, with a heart attack or stroke occurring every 40 seconds. High levels of LDL (“bad”) cholesterol are a main culprit for cardiovascular events. Amgen is committed to advancing a bold ambition: to halve the number of heart attacks and strokes by 2030. To change the cardiovascular disease treatment landscape, Amgen is working together alongside community stakeholders, healthcare systems and research institutions to drive urgency and action around the importance of LDL-C testing.

For more information about LDL and to learn how to get a free LDL-C test*, visit WhatIsMyLDL.com.

*Terms and conditions apply. Programs subject to change; quantities may be limited.

About Repatha® (evolocumab)

Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. Repatha has been studied for 12 years in 50 clinical trials with over 51,000 patients.

Repatha is approved in more than 75 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the European Union. Applications in other countries are pending.

Repatha® (evolocumab) Important U.S. Product Information 


INDICATIONS

Repatha® is indicated:

  • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
  • As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)–lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL–C
  • As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C
  • As an adjunct to other LDL–C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL–C

The safety and effectiveness of Repatha® have not been established in pediatric patients with HeFH or HoFH who are younger than 10 years old or in pediatric patients with other types of hyperlipidemia.


IMPORTANT SAFETY INFORMATION

  • Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
  • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
  • Adverse Reactions in Adults with Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

  • Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

  • Adverse Reactions in Pediatric Patients with HeFH: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, headache, oropharyngeal pain, influenza, and upper respiratory tract infection.
  • Adverse Reactions in Adults and Pediatric Patients with HoFH: In a 12-week study in 49 patients, the adverse reactions that occurred in at least two patients treated with Repatha® and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis. In an open-label extension study in 106 patients, including 14 pediatric patients, no new adverse reactions were observed.
  • Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please contact Amgen Medinfo at 800-77-AMGEN (800-772-6436) or 844-REPATHA (844-737-2842) regarding Repatha® availability or find more information, including full Prescribing Information, at www.amgen.com and www.Repatha.com.

About Amgen 
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads. 

Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon’s business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Further, any scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.

CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors) 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgens-phase-2-maritide-data-to-be-presented-at-the-american-diabetes-association-85th-scientific-sessions-302485214.html

SOURCE Amgen

Posted on

Synchrony and Payzer to Offer Seamless Home Improvement Financing Options

PR Newswire

Technology Integration to Transform Home Improvement Financing for Contractors and Their Customers


STAMFORD, Conn.
, June 18, 2025 /PRNewswire/ — Synchrony (NYSE: SYF), a premier financial services company, and Payzer, a WEX company that provides field service management software for residential contractors, have partnered to offer a comprehensive digital process designed to streamline sales and business transactions for contractors. This collaboration integrates Synchrony’s robust financing options directly into Payzer’s solution, making it easier for contractors to help customers fund their home improvement projects.

Empowering Contractors and Driving Growth
This collaboration offers substantial advantages for contractors using Payzer’s field service management solution, designed to streamline business operations, increase sales, and help contractors collect payment quickly:

  • All-in-One Solution: Contractors can now manage key aspects of a sale, including financing, within a single platform
  • Enhanced Sales Process: The integration highlights financing opportunities during the estimation process, potentially increasing sales and customer satisfaction
  • Expanded Network: The partnership leverages shared relationships with manufacturers and distributors, broadening the reach for both companies

According to Synchrony’s most recent Major Purchase Study, 75 percent of the dealers surveyed reported that offering financing options from Synchrony increased their average sales. Furthermore, the report found that 45 percent of major purchase shoppers surveyed with a credit card issued by Synchrony tend to spend more than those paying with other tenders. Paired with Payzer’s platform capabilities, such as proposal comparisons and integrated financing, offering Synchrony financing options becomes seamless.

“By integrating our financing directly into Payzer’s solution, we’re not just simplifying processes; we’re enhancing the entire home improvement journey for both contractors and consumers,” said Curtis Howse, EVP & CEO of Synchrony Home & Auto. “This partnership represents a significant step in our strategy to be present at every crucial point of the sales cycle, ultimately delivering more value to our partners and their customers.”

Enhancing the Financing Experience
The partnership between Synchrony and Payzer also brings significant benefits to customers. Contractors can now access Synchrony’s financing options seamlessly within Payzer’s platform, eliminating the need to switch between multiple systems. A full suite of 33 promotions is available to contractors, providing customers with flexible financing choices for their home improvement needs. The integration between Synchrony’s financing options and Payzer’s platform allows for a smooth, digital application process, including pre-qualification and instant credit decisions.

“This collaboration with Synchrony aligns perfectly with our commitment to providing contractors with best-in-class tools and services,” said Dylan Jones, Senior Vice President and General Manager, Mobility Growth, WEX. “By incorporating Synchrony’s financing options into our platforms, we’re giving our contractor network more choices and a competitive edge in the market.”

About Synchrony
Synchrony (NYSE: SYF) is a leading consumer financing company at the heart of American commerce and opportunity. From health to home, auto to retail, our Synchrony products have been serving the needs of people and businesses for nearly 100 years. We provide responsible access to credit and banking products to support healthier financial lives for tens of millions of people, enabling them to access the things that matter to them. Additionally, through our innovative products and experiences, we support the growth and operations of some of the country’s most respected brands, as well as more than 400,000 small and midsize businesses and health and wellness providers that Americans rely on. Synchrony is proud to be ranked as the country’s #2 Best Company to Work For® by Fortune magazine and Great Place to Work®. For more information, visit www.synchrony.com.

About Payzer
Payzer®, a WEX™ company, is a leading provider of software solutions for contractors in the home improvement industry. The company’s solution, Payzerware, offers comprehensive tools for managing all aspects of contracting businesses, from estimations and sales to payments and financing. For further information, visit: www.payzer.com.

Media Contacts:

Lauren Devilbiss

Synchrony
[email protected]  

Johnston Farrow
WEX
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/synchrony-and-payzer-to-offer-seamless-home-improvement-financing-options-302478326.html

SOURCE Synchrony

Posted on

ibex Donates $25,000 to Wounded Warrior Project

Kicks off ongoing community support initiative

WASHINGTON, June 18, 2025 (GLOBE NEWSWIRE) — ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and AI-powered customer engagement technology solutions, is proud to announce a $25,000 donation to Wounded Warrior Project® (WWP) as part of ibex CaresTM, the company’s global philanthropic program. This contribution supports WWP’s mission, which focuses on the total well-being of post-9/11 wounded, ill, or injured veterans. From PTSD treatments to essential long-term care, the nonprofit is empowering warriors to thrive – physically, mentally, and financially – for a lifetime.

WWP began in 2003 by delivering backpacks filled with comfort items to the bedsides of wounded warriors – along with a powerful promise to stand by them as they healed and rebuilt their lives. Today, WWP is the nation’s leading veterans service organization, providing essential lifelines to warriors, their families, and caregivers. Thanks to support from generous Americans and organizations, WWP can serve warriors and their families at no cost to them.

“On behalf of ibex and our many veterans, we are proud to make this donation to help support our nation’s wounded veterans,” said ibex Chief People Officer Paul Inson. “Supporting the mission of Wounded Warrior Project fits perfectly with our core values of compassion and community service. We believe it’s not just a responsibility but a privilege to give back to those who have given so much for our country.”

The donation is part of ibex Cares, which supports charitable organizations across ibex’s operational regions. ibex Cares also encourages employees to volunteer and donate to local causes, promoting meaningful connections and driving positive change in communities worldwide.

“We must never forget the cost of freedom,” said Brea Kratzert Todd, WWP Vice President of Business Development. “Supporters like ibex make it possible for Wounded Warrior Project to provide life-changing programs and be there for warriors throughout their lifetime.”

As ibex continues to grow, the company remains dedicated to expanding its charitable impact and nurturing a culture of giving back across its global operations.

“I applaud our team for their amazing generosity and compassion,” said Christy O’Connor, Chief Legal Officer at ibex. “I am personally involved with Wounded Warrior’s Battalion West, where my dog has been a therapy dog to wounded warriors for six years and helped save numerous lives. Giving is in our DNA and is just one more thing that makes ibex special.”


About ibex

ibex delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage and retain valuable customers. Today, ibex operates a global CX delivery center model consisting of 31 operations facilities around the world, while deploying next generation technology to drive superior customer experiences for many of the world’s leading companies across retail, e-commerce, healthcare, fintech, utilities and logistics.

ibex leverages its diverse global team of approximately 31,000 employees together with industry-leading technology, including the AI-powered ibex Wave iX solutions suite, to manage nearly 175 million critical customer interactions, adding over $2.2B in lifetime customer revenue each year and driving a truly differentiated customer experience. To learn more, visit our website at ibex.co and connect with us on LinkedIn.


About Wounded Warrior Project

Wounded Warrior Project is our nation’s leading veteran services organization, focused on the total well-being of post-9/11 wounded, ill, or injured veterans. Our programs, advocacy, and awareness efforts help warriors thrive, provide essential lifelines to families and caregivers, and prevent veteran suicides. Learn more about Wounded Warrior Project.


Media Contact:


Dan Burris
ibex
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ee99ff99-ccc2-43f4-a5af-da11ebe31725



Posted on

Satellogic Poised to Deliver Its NextGen Satellite and Technology Transfer for Malaysia’s Earth Observation Satellite Program

Satellogic to Provide Advanced High-Resolution Satellite to Support Uzma Berhad and Malaysia’s National Space Ambitions

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) — Satellogic, Inc. (NASDAQ: SATL), a leader in satellite manufacturing and high-resolution Earth observation data, is pleased to announce that Uzma Berhad, and by extension Satellogic as Uzma’s Technology Partner, has been selected as the successful bidder to lead the Malaysian High-Resolution Earth Observation Satellite Project (MHREOSP) for the Government of Malaysia.

As a technology partner, Satellogic will design, develop, assemble, integrate and test a state-of-the-art high resolution satellite with active involvement of Malaysian personnel. This newest evolution of Satellogic’s proven platform, is built on the extensive heritage from over 50 NewSat satellites and features key upgrades, including superior National Imagery Interpretability Rating Scales (NIIRS) ratings, larger optics and enhanced sensor design, to deliver 50cm resolution across all spectral bands. Final integration and testing are planned to take place in Malaysia in collaboration with Uzma and local parties to support meaningful homegrown capacity development.

This collaboration builds on the successful deployment of UzmaSAT-1 and underscores Satellogic’s commitment to delivering agile space solutions to its customers around the world. “Satellogic brings proven satellite technology and a commitment to agile innovation that aligns with our goals and the nation’s space aspirations, supporting the Malaysia Space Exploration 2030 Action Plan,” said Dato’ Kamarul Redzuan Muhamed, Group CEO of Uzma Berhad. “With the Government’s guidance, Satellogic’s expertise, and our homegrown talents, we are enabling Malaysia to leap forward in its geospatial intelligence capabilities and supporting the long-term sustainability of our national infrastructure and environment by nurturing local talent through knowledge sharing, technology transfer, and exposure to satellite technology. We look forward to help grow the ecosystem further, guided by the Malaysian Government and its agencies, including Malaysia’s Ministry of Science, Technology and Innovation (MOSTI), MYSA, the Public-Private Partnership Unit (UKAS), and Malaysian Industry-Government Group for High Technology (MIGHT).”

The selection strengthens Satellogic’s expanding presence in Asia and reinforces its mission to democratize access to state-of-the-art space technology.
“This partnership harnesses the power of commercial space to strengthen national sovereignty through proprietary space access,” said Emiliano Kargieman, CEO & Co-Founder of Satellogic. “We’re proud to support Malaysia’s forward-looking vision for space and to work alongside Uzma and GeospatialAI in delivering capabilities that will drive national resilience and innovation”

About Satellogic

Founded in 2010 by Emiliano Kargieman and Gerardo Richarte, Satellogic (NASDAQ: SATL) is the first vertically integrated geospatial company, driving real outcomes with planetary-scale insights. Satellogic is creating and continuously enhancing the first scalable, fully automated EO platform with the ability to remap the entire planet at both high-frequency and high-resolution, providing accessible and affordable solutions for customers.

Satellogic’s mission is to democratize access to geospatial data through its information platform of high resolution images to help solve the world’s most pressing problems including climate change, energy supply, and food security. Using its patented Earth imaging technology, Satellogic unlocks the power of EO to deliver high-quality, planetary insights at the lowest cost in the industry.

With more than a decade of experience in space, Satellogic has proven technology and a strong track record of delivering satellites to orbit and high-resolution data to customers at the right price point.

To learn more, please visit: http://www.satellogic.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intends”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on Satellogic’s current expectations and beliefs concerning future developments and their potential effects on Satellogic and include statements concerning Satellogic’s strategic realignment as a U.S. company, and the visibility and high growth opportunities it will provide in connection therewith. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These statements are based on various assumptions, whether or not identified in this press release. These forward-looking statements are provided for illustrative purposes only and are not intended to serve, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ
from assumptions. Many actual events and circumstances are beyond the control of Satellogic. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to generate revenue as expected, including due to challenges created by macroeconomic concerns, geopolitical uncertainty (e.g., trade relationships), financial market fluctuations and related factors, (ii) our ability to effectively market and sell our EO services and to convert contracted revenues and our pipeline of potential contracts into actual revenues, (iii) risks related to the secured convertible notes, (iv) the potential loss of one or more of our largest customers, (v) the considerable time and expense related to our sales efforts and the length and unpredictability of our sales cycle, (vi) risks and uncertainties associated with defense-related contracts, (vii) risk related to our pricing structure, (viii) our ability to scale production of our satellites as planned, (ix) unforeseen risks, challenges and uncertainties related to our expansion into new business lines, (x) our dependence on third parties, including SpaceX, to transport and launch our satellites into space, (xi) our reliance on third-party vendors and manufacturers to build and provide certain satellite components, products, or services and the inability of these vendors and manufacturers to meet our needs, (xii) our dependence on ground station and cloud-based computing infrastructure operated by third pirates for value-added services, and any errors, disruption, performance problems, or failure in their or our operational infrastructure, (xiii) risk related to certain minimum service requirements in our customer contracts, (xiv) market acceptance of our EO services and our dependence upon our ability to keep pace with the latest technological advances, including those related to artificial intelligence and machine learning, (xv) our ability to identify suitable acquisition candidates or consummate acquisitions on acceptable terms, or our ability to successfully integrate acquisitions, (xvi) competition for EO services, (xvii) challenges with international operations or unexpected changes to the regulatory environment in certain markets, (xviii) unknown defects or errors in our products, (xix) risk related to the capital-intensive nature of our business and our ability to raise adequate capital to finance our business strategies, (xx) uncertainties beyond our control related to the production, launch, commissioning, and/or operation of our satellites and related ground systems, software and analytic technologies, (xxi) the failure of the market for EO services to achieve the growth potential we expect, (xxii) risks related to our satellites and related equipment becoming impaired, (xxiii) risks related to the failure of our satellites to operate as intended, (xxiv) production and launch delays, launch failures, and damage or destruction to our satellites during launch, (xxv) the impact of natural disasters, unusual or prolonged unfavorable weather conditions, epidemic outbreaks, terrorist acts and geopolitical events (including the ongoing conflicts between Russia and Ukraine, in the Gaza Strip and the Red Sea region) on our business and satellite launch schedules and (xxvi) the anticipated benefits of the domestication may not materialize. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Satellogic’s Annual Report on Form 10-K and other documents filed or to be filed by Satellogic from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Satellogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Satellogic can give no assurance that it will achieve its expectations.

Contacts

Investor Relations:

Ryan Driver, VP of Strategy & Corporate Development 

[email protected]

Media Relations:

Satellogic

[email protected]

Uzma Berhad

[email protected]



Posted on

Tenable Research Finds Pervasive Cloud Misconfigurations Exposing Critical Data and Secrets

Insecure cloud configurations create widespread risk, highlighting the urgent need for unified cloud exposure management

COLUMBIA, Md., June 18, 2025 (GLOBE NEWSWIRE) — Tenable®, the exposure management company, today released its 2025 Cloud Security Risk Report. The research revealed that 9% of publicly accessible cloud storage contains sensitive data, 97% of which is classified as restricted or confidential. These exposures increase the risk of exploitation, particularly when paired with misconfigurations or embedded secrets.

Cloud environments face dramatically increased risk due to exposed sensitive data, misconfigurations, underlying vulnerabilities and poorly stored secrets – such as passwords, API keys and credentials. The 2025 Cloud Security Risk Report provides a deep dive into the most prominent cloud security issues impacting data, identity, workload and AI resources and offers practical mitigation strategies to help organizations proactively reduce risk and close critical gaps.

Key findings from the report include:

  • Secrets found in diverse cloud resources are putting organizations at risk: Over half of organizations (54%) store at least one secret directly in Amazon Web Services (AWS) Elastic Container Service (ECS) task definitions — creating a direct attack path. Similar issues were found among organizations using Google Cloud Platform (GCP) Cloud Run (52%) and Microsoft Azure Logic Apps workflows (31%). Alarmingly, 3.5% of all AWS Elastic Compute Cloud (EC2) instances contain secrets in user data — major risk given how widely EC2 is used.
  • Cloud workload security is improving, but toxic combinations persist: While the number of organizations with a “toxic cloud trilogy” – a workload that is publicly exposed, critically vulnerable, and highly privileged – has decreased from 38% to 29%, this dangerous combination still represents a significant and common risk.
  • Using Identity Providers (IdPs) alone doesn’t eliminate risk: While 83% of AWS organizations are exercising best practices in using IdP services to manage their cloud identities, overly-permissive defaults, excessive entitlements, and standing permissions still expose them to identity-based threats.

“Despite the security incidents we have witnessed over the past few years, organizations continue to leave critical cloud assets, from sensitive data to secrets, exposed through avoidable misconfigurations,” said Ari Eitan, Director of Cloud Security Research, Tenable.

“The path for attackers is often simple: exploit public access, steal embedded secrets or abuse overprivileged identities. To close these gaps, security teams need full visibility across their environments and the ability to prioritize and automate remediation before threats escalate. The cloud demands continuous, proactive risk management, and not reactive patchwork.”

The report reflects findings by the Tenable Cloud Research team based on telemetry from workloads across diverse public cloud and enterprise environments, analyzed from October 2024 through March 2025. To download the report today, please visit: https://www.tenable.com/cyber-exposure/tenable-cloud-security-risk-report-2025

More information on Tenable Cloud Security is available at: https://www.tenable.com/cloud-security.

About Tenable

Tenable® is the exposure management company, exposing and closing the cybersecurity gaps that erode business value, reputation and trust. The company’s AI-powered exposure management platform radically unifies security visibility, insight and action across the attack surface, equipping modern organizations to protect against attacks from IT infrastructure to cloud environments to critical infrastructure and everywhere in between. By protecting enterprises from security exposure, Tenable reduces business risk for more than 44,000 customers around the globe. Learn more at tenable.com.

Media Contact:

Tenable
[email protected]



Posted on

Wix Further Expands into Vibe Coding with Acquisition of Base44, a Hyper-Growth Startup that Simplifies Web and App Creation with AI

Base44 delivers effortless, code-free digital creation through an intuitive, conversational AI experience, which is expected to expand Wix’s reach to new audiences worldwide

NEW YORK— Today Wix.com Ltd. (Nasdaq: WIX), the leading SaaS website builder platform globally1, announced its acquisition of Base44, an AI-powered platform that enables anyone to create fully-functional, custom software solutions and applications using natural language, without the need for traditional coding. The acquisition adds a powerful new arm to Wix’s AI portfolio, expanding its suite of intelligent solutions that empower anyone to build and grow online. 

The tech landscape is undergoing a major transformation as vibe coding gains momentum, shifting creation from manual development to intent-driven software development. This new approach allows people to simply express what they want to build, while intelligent agents do the heavy lifting. As demand grows for tools that turn ideas into reality through conversation and intuition rather than code, Wix is working to make the digital world more accessible and creative than ever before. Read CEO Avishai Abrahami’s blog about his vision and the way Wix is shaping this future here.

Base44’s unique approach offers a fully automated, chat-based interface that manages technical details behind the scenes, from databases and authentication to deployment – removing the need for third-party integrations or manual setup. This groundbreaking approach opens the door for anyone, regardless of technical expertise, to create production-ready, scalable applications quickly and effortlessly. With proven traction in the market, including B2B partnerships with leaders like eToro and SimilarWeb, Base44 is a powerful addition to the Wix AI portfolio – furthering the company’s mission to make innovation accessible to creators and businesses worldwide.

“This acquisition marks a pivotal milestone in Wix’s commitment to transforming creation online,” said Avishai Abrahami, CEO and Co-founder of Wix. “Maor and his team at Base44 bring cutting-edge technology, strong market penetration, and visionary leadership that seamlessly align with Wix’s dedication to enabling users at all levels of expertise to express their intent while intelligent agents manage execution. Maor’s exceptional talent and innovative mindset will reinforce Wix’s mission to push the boundaries of AI-driven creation and  accelerate the evolution of intuitive, intelligent tools that redefine how digital experiences are built and enjoyed.”

“I honestly can’t think of a better fit. Wix is probably the only company that can help Base44 achieve the scale and distribution it needs while maintaining, if not accelerating, our product velocity,” said Maor Shlomo, CEO of Base44. “Our market is massive. It has the potential to replace entire software categories by enabling people to create software instead of buying it. Wix’s DNA – its customer obsession, innovation, and speed – perfectly aligns with ours, and its scale will catapult Base44 forward at exactly the right time.”

Base44 will continue to operate as a distinct product and business, maintaining its unique identity and momentum while benefiting from the scale and support of Wix.

Transaction Terms

Under the terms of the agreement, Wix acquired Base44 for initial consideration of approximately $80 million plus additional earn-out payments paid through 2029 predicated upon certain performance metrics.

We expect this transaction to have an inconsequential contribution to 2025 bookings and revenue. We expect to incur approximately $25 million in retention bonus payments paid to Base44 employees in 2025 as part of the above initial consideration paid on the transaction, which will be excluded from non-GAAP and free cash flow (FCF) results.


About Wix.com Ltd.


Wix
 is the leading SaaS website builder platform1 to create, manage and grow a digital presence. Founded  in 2006, Wix is a comprehensive platform providing users – self-creators, agencies, enterprises, and more – with industry-leading performance, security, AI capabilities and a reliable infrastructure. Offering a wide range of commerce and business solutions, advanced SEO and marketing tools, the platform enables users to take full ownership of their brand, their data and their relationships with their customers. With a focus on continuous innovation and delivery of new features and products, users can seamlessly build a powerful and high-end digital presence for themselves or their clients. 

For more about Wix, please visit our Press Room
Media Relations Contact:  [email protected]  

1 Based on number of active live sites as reported by competitors’ figures, independent third-party data and internal data as of Q1 2025.

About Base44


Base44
 is an innovative AI-powered platform that enables users to build custom software applications effortlessly using natural language, eliminating the need for traditional coding. Founded with a vision to democratize software creation, Base44 combines cutting-edge AI technologies—including code generation and multi-agent orchestration—to empower self-creators, developers, and businesses to rapidly design, deploy, and scale tailored digital solutions. With a growing user base and a focus on seamless, intuitive experiences, Base44 drives the future of no-code development by unlocking new levels of creativity and efficiency for a diverse range of users.

Forward-Looking Statements

This document contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements may be identified by words like “anticipate,” “assume,” “believe,” “aim,” “forecast,” “indication,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “subject,” “project,” “outlook,” “future,” “will,” “seek” and similar terms or phrases. The forward-looking statements contained in this document are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, our ability to achieve the expected benefits from the acquisition of Base44, our ability to attract and retain registered users and partners, and generate new premium subscriptions and additional business solutions as we continuously adjust our marketing strategy and customer care; maintenance of our brand and reputation, and generation of revenue from sources other than premium subscriptions; risks associated with international operations and the use of platform in various countries; risks related to the macroeconomic environment and ongoing global conflicts; security risks and payment risks and fluctuations in foreign currency exchange rates; failures of third-party hardware, software and infrastructure on which we rely, or failure to manage the operation of our infrastructure; adverse market conditions, including inflation, interest rates and other adverse developments that may adversely affect our cash balances and investment portfolio; our history of operating losses and inability to achieve sustained profitability; downturns or upturns in sales are not immediately reflected in full in our operating results; our ability to repurchase our ordinary shares and/or 0.00% Convertible Senior Notes due 2025 pursuant to our repurchase program; our ability to raise capital when needed or on acceptable terms; risks related to acquisitions and investments, pricing decisions, pandemics, natural disasters and other catastrophic events; our ability to develop and introduce new products and services, as well as maintain third-party products and our ability to keep up with rapid changes in design and technology; our ability to attract and retain qualified employees and key personnel; our ability to attract a diversified customer base and increased competition; our ability to maintain compatibility of our platform and solutions with changes in third-party applications and changes to technologies used in our solutions; our ability to acquire and service small business users; risks related to security breaches and unauthorized access to data or cyberattacks; our expectation regarding the uncertain future relationship between the United States and other countries with respect to trade policies, taxes, government regulations, and tariffs; our ability to comply with the regulations applicable to our operations, including new governmental regulations regarding the internet, consumer protection, artificial intelligence (“AI”), privacy and data protection laws and regulations, as well as contractual privacy and data protection obligations; risks relating to intellectual property, including infringements, litigation and claims, and our ability to maintain and protect our intellectual property rights and proprietary information; our expectations regarding the outcome of any regulatory investigation or litigation, including class actions; risks related to the development and integration of AI, generative AI, agentic AI, machine learning, and similar tools into our offerings, and compliance with the regulatory environment impacting AI and AI-related activities; risks related to activities of registered users or content of their websites, and risks related to domain names and industry regulations; risks related to compliance with laws and regulations, including those related to economic sanctions, tariffs, export controls, anti-corruption and anti-money laundering, antitrust, and consumer protection, and changes in these laws and regulations; risks related to tax, including application of indirect taxes, tax laws, changes in tax laws or changes in provision for income tax and examination of income tax returns; risks related to ordinary shares, activist shareholders, and our status as a foreign private issuer; risks related to our incorporation and location in Israel, including conflicts in the area; our expectations regarding future changes in our cost of revenues and our operating expenses on an absolute basis and as a percentage of our revenues; our planned level of capital expenditures and our belief that our existing cash and cash from operations will be sufficient to fund our operations for at least the next 12 months and for the foreseeable future; and our ability to enter into new markets and attract new customer demographics, including our ability to successfully attract new partners and large enterprise-level users and to grow our activities, including through the adoption of our Wix Studio product, with these customer types as anticipated and other factors discussed under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 21, 2025. The preceding list is not intended to be an exhaustive list of all of the risks that may impact our forward-looking statements. Any forward-looking statement made by us in this press release speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Attachment



Posted on

Moomoo Gears Up to Celebrate New York Mets’ 50th Victory with a $20,000 Fan Giveaway, Announces 25th Win Prize Recipient with $10,000

JERSEY CITY, N.J., June 18, 2025 (GLOBE NEWSWIRE) — Moomoo, a global investment and trading platform, is getting ready to celebrate with New York Mets fans with a $20,000 giveaway as the Mets approach the exciting 50th win of the 2025 MLB season. Moomoo also congratulates the Mets on achieving their 25th win by giving $10,000 to the sweepstakes winner – H Smith from Queens, New York. This milestone also activated the first major prize in moomoo’s season-long fan engagement campaign.

As part of the strategic partnership with the Mets, moomoo pledged to contribute $10,000 to a special prize fund for every team victory. With the Mets reaching 25 wins, H Smith becomes the first moomoo user to win the first prize of this ongoing sweepstakes. As the season progresses, subsequent milestone achievements including 50, 75, and 100 wins will lead to increased prizes for each milestone and a potential $1 million grand prize for a lucky moomoo investor.

At this time, fans are encouraged to create their moomoo account and make a qualifying deposit soon for a chance to win the $20,000 prize after the team records its 50th win.

“We’re excited to officially kickoff the prize portion of this special partnership with the Mets, and reward Mets fans and moomoo users by creating special experiences like this,” said Neil McDonald, moomoo US’s CEO. “Our partnership with the Mets aims at creating memorable experiences for fans and investors alike and we can’t wait to see what the rest of the season will bring.”

In addition to the cash awards, moomoo will host Moomoo Mondays at Mets games: every Monday home game during the 2025 regular season moomoo will be giving away up to 500 free tickets to fans. To be eligible, fans will simply show the moomoo Monday Mets ticket offer on their moomoo app at the Mets Box Office at the ballpark. Each Monday, fans can expect prizes and surprises during their Citi Field experience, including free promotional items.

About moomoo

Moomoo is a leading global investment and trading platform dedicated to empowering investors with user-friendly tools, data, and insights. Our platform is designed to provide essential information and technology, enabling users to make more-informed investment decisions. With advanced charting tools, pro-level analytical features, moomoo evolves alongside our users, fostering a dynamic community where investors can share, learn, and grow together.
Founded in the U.S., moomoo operates globally, serving investors in countries such as the US, Singapore, Australia, Japan, Canada and Malaysia. As a subsidiary of a Nasdaq-listed Futu Holdings (FUTU), we take pride in our role as a global strategic partner of the Nasdaq, earning numerous international accolades from renowned industry leaders such as Benzinga and Fintech Breakthrough. Moomoo has also received multiple awards in the US, Singapore, and Australia for its innovative, inclusive approach to investing.

For more information, please visit moomoo’s official website at www.moomoo.com or feel free to email us: [email protected].

Purchase will not improve chances of winning. Void where prohibited. 18+. Open to permanent legal U.S. residents residing in NY, NJ, CT, or PA. Starts 4/4/2025. Various deadlines may apply. Entries must be received by 11:59 pm ET on 9/28/2025 or earlier if the Mets win 100 games. Enter for free at Free entry link. Prize restrictions apply. For details/Official Rules visit bit.ly/moomoomillion_Rules

The Mets are not affiliated with moomoo or its affiliates. Moomoo is a financial information and trading app offered by Moomoo Technologies Inc. Securities offered through Moomoo Financial Inc., Member FINRA/SIPC. Investing is risky.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3d63025a-3e11-40b6-9a13-20cfa71d5a5e



Posted on

INVO Fertility Expands Telehealth Capabilities at Its Wisconsin Fertility Institute

MIDDLETON, Wis. and SARASOTA, Fla., June 18, 2025 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, is thrilled to announce the expansion of its telehealth capabilities at its Wisconsin Fertility Institute center, designed to help expand access, and in a more patient-convenient manner, to expert fertility care and help support more families on their journey to parenthood.

Dr. Gretchen Collins, medical director and Reproductive Endocrinologist and Infertility specialist at Wisconsin Fertility Institute, is now further licensed in Illinois, Minnesota, Iowa, Montana, Colorado, Georgia, Alabama, Kansas, and Indiana.

This telehealth platform allows prospective parents to connect with Wisconsin Fertility Institute’s team of providers from the comfort of their homes. Through secure virtual consultations, patients can receive personalized fertility assessments, treatment planning, and ongoing support, making high-quality care more accessible and convenient than ever before.

“Our mission has always been to empower families with the tools and expertise they need to achieve their dreams of parenthood,” said Steve Shum, CEO at INVO Fertility. “By integrating telehealth into our services, we’re breaking down geographic barriers and providing compassionate, expert care to individuals and couples, no matter where they are located.”

The telehealth platform is designed to streamline the fertility journey, offering virtual appointments for initial consultations, follow-up visits, and cycle monitoring discussions. While telehealth enhances accessibility for consultations and planning, all egg retrievals and embryo transfers will continue to take place at Wisconsin Fertility Institute’s state-of-the-art clinic where patients receive hands-on care using the latest advancements in reproductive technology.

This expansion of services is expected to significantly broaden Wisconsin Fertility Institute’s reach, particularly for those in underserved or rural areas who may face challenges accessing specialized fertility care. By combining the convenience of telehealth with the expertise of in-clinic procedures, Wisconsin Fertility Institute is poised to help more families navigate the complexities of fertility treatment with confidence and ease.

To learn more about Wisconsin Fertility Institute, visit www.Wisconsinfertility.com or contact the clinic at 608-824-0075 for more details.

About INVO Fertility

We are a healthcare fertility company dedicated to expanding assisted reproductive technology (”ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. The IVC procedure provides patients with a more natural, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination (“IUI”). For more information, please visit www.invofertility.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

INVO Fertility, Inc.

Steve Shum, CEO

978-878-9505
[email protected]

Investor Contact

Lytham Partners, LLC

Robert Blum

602-889-9700
[email protected]



Posted on

IZEA Announces Final Results of its Modified Dutch Auction Tender Offer

ORLANDO, Fla., June 18, 2025 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading influencer marketing company that makes Creator Economy solutions for marketers, announced today the preliminary results of its modified “Dutch auction” tender offer (the “Offer”) to repurchase up to 8,700,000 of its common stock at a price of $2.80 per share (the “Purchase Price”), less any applicable withholding taxes and without interest, using cash on hand. The Offer expired at 5:00 P.M., Eastern time, on June 16, 2025 (the “Expiration Date”).

Based on the Final count by Broadridge Financial Solutions, the depositary for the Tender Offer (the “Depositary”), a total of 38,682 shares were properly tendered and not properly withdrawn in the Tender Offer. In accordance with the terms and conditions of the Tender Offer, the Company has accepted for purchase 38,682 shares in the Tender Offer for an aggregated cost of approximately $108,310, excluding all fees and expenses. The shares acquired pursuant to the Tender Offer represent approximately 0.23% of the Company’s outstanding shares as of June 16, 2025.

The Depositary will promptly issue payment in cash for the shares validly tendered and accepted for purchase in the Tender Offer, less any applicable withholding taxes and without interest. Shares tendered and not accepted for purchase will be returned promptly to stockholders by the Depositary in accordance with applicable law. Following the purchase of shares in the Tender Offer, approximately $8.6 million will remain outstanding under the Company’s stock repurchase obligations.

Important Information

The Offer described in this press release has commenced and will not be made to any person in any jurisdiction in which either the Offer, or solicitation or sale thereof, is unlawful. This announcement is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell any securities of IZEA. The Offer is only being made pursuant to the Offer to Purchase, letter of transmittal, and related materials filed with the SEC as part of a Schedule TO. Stockholders are strongly encouraged to read the tender offer statement on Schedule TO, the Offer to Purchase, and other related documents, as they contain important information and an explanation of the terms and conditions for participation. Stockholders may obtain a free copy of the tender offer statement on Schedule TO, the offer to purchase, letter of transmittal and other documents that the Company will be filing with the SEC at the SEC’s website at www.sec.gov or from the information agent for the Offer, MacKenzie Partners, by phone at 1-800-322-2885, or by e-mail addressed to [email protected].

About IZEA Worldwide, Inc.

IZEA Worldwide, Inc. (“IZEA”), is an influencer marketing company with a mission to make creator economy solutions for marketers. We do this by lighting up the Creator Economy with IZEAs—our strategies, campaigns, and solutions that build brands and drive demand. Since launching the industry’s first-ever influencer marketing platform in 2006, IZEA has facilitated nearly 4 million collaborations between brands and creators.

Press Contact

Matt Gray
IZEA Worldwide, Inc.
Phone: 407-674-6911
Email: [email protected] 



Posted on

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

FDA priority review and approval based on interim results sets a positive precedent, paving the path for future Multikine approval

Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS) by 30% compared with standard of care in patients whose tumors expressed higher PD-L1 without demonstrating improvement in overall survival

Pre-operative treatments from CEL-SCI and Merck have the potential to offer clinical benefit for locally advanced resectable head and neck cancer patients across the PD-L1 expression spectrum

VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation(NYSE American: CVM) today applauded the U.S. Food and Drug Administration’s (FDA) approval of Merck’s KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test. Merck’s application was granted the FDA’s priority review on February 25, 2025, and regulatory approval was granted on June 13, 2025, based on interim results from Keytruda’s Phase 3 KEYNOTE-689 trial.

Last week the FDA approved Keytruda as a perioperative (before and after surgery) treatment for resectable locally advanced head and neck cancer patients whose tumors express PD-L1 at a positive level. In Merck’s Phase 3 KEYNOTE-689 trial, Keytruda reduced the risk of recurrence and progression by 30%, compared with standard of care, in patients whose tumors expressed PD-L1 (CPS ≥1). The study did not show an improvement in overall survival. Patients with low to zero levels of PD-L1 did not benefit from Keytruda.

In contrast to the results of the KEYNOTE-689, CEL-SCI’s Phase 3 study showed that Multikine* treated patients whose tumors expressed low (Tumor Proportion Score [TPS <10]) to zero PD-L1, had their risk of death reduced by 66% (hazard ratio 0.34, 95% CI [0.18, 0.65], p=0.0012) and extended the 5-year overall survival to 73% compared to 45% in the standard of care, log rank p=0.0015. About 70% of the patients in CEL-SCI’s Phase 3 study had low to zero levels of PD-L1.

“It is encouraging for CEL-SCI that Merck’s Keytruda application received the FDA’s priority review and that marketing approval was given based on a Phase 3 study’s first pre-specified interim analysis. CEL-SCI has received the FDA’s go-ahead for a confirmatory Registration Study with 212 patients based on results from the completed Multikine Phase 3 study in head and neck cancer patients. The patients in the Phase 3 study that benefited from Multikine pre-surgery treatment showed an almost 4-year median overall survival advantage over control, and pre-surgery tumor responses to Multikine predicted survival benefit. The Keytruda approval based on pre-specified interim results strongly implies that Multikine has the potential for accelerated regulatory approval based on favorable post-surgical tumor responses,” stated CEL-SCI’s CEO, Geert Kersten.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it should provide the greatest possible impact on survival. Multikine is designed to help the immune system “target” the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Based on the data from the completed randomized controlled Phase 3 study, the FDA concurred with CEL-SCI’s target patient selection criteria and gave the go-ahead to conduct a confirmatory Registration Study. The study will enroll 212 newly diagnosed locally advanced primary treatment naïve resectable head and neck cancer patients.

The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words “intends,” “believes,” “anticipated,” “plans” and “expects,” and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company’s potential products, inability to raise the necessary capital, inability to finalize a partnering agreement and the risk factors set forth from time to time in CEL-SCI’s filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

COMPANY CONTACT:

Gavin de Windt

CEL-SCI Corporation

(703) 506-9460

KEYWORDS: United States North America District of Columbia Virginia

INDUSTRY KEYWORDS: Surgery FDA Clinical Trials Biotechnology Other Health Radiology Health Pharmaceutical Oncology

MEDIA:

Logo
Logo